GGrantIndex
← Search

SOUTHWEST ONCOLOGY GROUP - OPERATIONS OFFICE

$9,490,764U10FY2008CANIH

University Of Michigan At Ann Arbor, Ann Arbor MI

Investigators

Linked publications, trials & patents

Trial NCT03015701Trial NCT02196181Trial NCT02134912Trial NCT02042443Trial NCT01946516Trial NCT01925131Trial NCT01903811Trial NCT01902173Trial NCT01802333Trial NCT01688973Trial NCT01674140Trial NCT01668719Trial NCT01658943Trial NCT01575535Trial NCT01563861Trial NCT01522976Trial NCT01503541Trial NCT01498289Trial NCT01466881Trial NCT01434329Trial NCT01412879Trial NCT01386385Trial NCT01360125Trial NCT01359592Trial NCT01338974Trial NCT01309672Trial NCT01272037Trial NCT01260701Trial NCT01120275Trial NCT01120249Trial NCT01120236Trial NCT01093222Trial NCT01064648Trial NCT01059734Trial NCT01055301Trial NCT01015560Trial NCT01000558Trial NCT00996047Trial NCT00985699Trial NCT00972751Trial NCT00972478Trial NCT00949013Trial NCT00946712Trial NCT00945815Trial NCT00939328Trial NCT00937937Trial NCT00929591Trial NCT00920010Trial NCT00919425Trial NCT00919139Trial NCT00900484Trial NCT00900263Trial NCT00900042Trial NCT00899743Trial NCT00899171Trial NCT00898872Trial NCT00898183Trial NCT00898066Trial NCT00897091Trial NCT00873808Trial NCT00872989Trial NCT00856492Trial NCT00840177Trial NCT00822120Trial NCT00792948Trial NCT00792701Trial NCT00789958Trial NCT00770224Trial NCT00770120Trial NCT00723658Trial NCT00686166Trial NCT00684996Trial NCT00661193Trial NCT00658814Trial NCT00644228Trial NCT00617708Trial NCT00608361Trial NCT00569127Trial NCT00551460Trial NCT00499369Trial NCT00492856Trial NCT00450281Trial NCT00445848Trial NCT00445601Trial NCT00436332Trial NCT00433446Trial NCT00410813Trial NCT00382018Trial NCT00376961Trial NCT00368992Trial NCT00352443Trial NCT00352365Trial NCT00337168Trial NCT00337129Trial NCT00335959Trial NCT00334815Trial NCT00329641Trial NCT00324987Trial NCT00311545Trial NCT00305734

Abstract

DESCRIPTION (provided by applicant): The Southwest Oncology Group is an adult, multi-disease, multi-modality clinical cancer research organization with 35 Member Institutions, 29 Community Clinical Oncology Program (CCOP) institutions, including 7 Minority-Based CCOPs, 27 Urologic Cancer Outreach Program (UCOP) members, and a network of 1,036 Affiliate Program investigators at 189 offices and hospitals, and 12 institutions participating in the CTEP Minority program. A special emphasis of the Group is managed by the renamed Committee on Special Populations, established in 1992. The committee's research and education agenda has broadened to include: women (or men), older cancer patients, cancer survivors, and racial/ethnic minority groups (African-American, Hispanic Americans and Asian American Pacific Islanders). Involving patient advocates in Group activities is an important role of this committee. The committee report details the cross-committee research and publications. The moral and ethical conduct of clinical research by the group members is emphasized by ethics training, the conflict of interest policy, affirmation of integrity and data and safety monitoring. In addition to the presentation of correlative sciences activities tied to tumor banks related to disease committees, we propose a Correlative Sciences Committee, which will provide oversight of science and quality assurance of assay technology across the six disease committee correlative science programs in the Group. There are three new initiatives in this application. Two new adult medical oncology Intergroup proposals, one dealing with advanced gynecologic cancer, the U.S. Gynecology Intergroup, and the second dealing with sarcomas, The U.S./Canada Sarcoma Intergroup. The third is the Early Therapeutics Committee, which will take advantage of the 10 institutions in the Group who hold Phase I NCI funded U-01s. This will be possible with the new Web-Based, Multi-User Phase I Monitoring System implemented by our Statistical Center.

View original record on NIH RePORTER →